Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants.

BACKGROUND Statins have been shown to reduce the risk of all-cause mortality among individuals with clinical history of coronary heart disease. However, it remains uncertain whether statins have similar mortality benefit in a high-risk primary prevention setting. Notably, all systematic reviews to date included trials that in part incorporated participants with prior cardiovascular disease (CVD) at baseline. Our objective was to reliably determine if statin therapy reduces all-cause mortality among intermediate to high-risk individuals without a history of CVD. DATA SOURCES Trials were identified through computerized literature searches of MEDLINE and Cochrane databases (January 1970-May 2009) using terms related to statins, clinical trials, and cardiovascular end points and through bibliographies of retrieved studies. STUDY SELECTION Prospective, randomized controlled trials of statin therapy performed in individuals free from CVD at baseline and that reported details, or could supply data, on all-cause mortality. DATA EXTRACTION Relevant data including the number of patients randomized, mean duration of follow-up, and the number of incident deaths were obtained from the principal publication or by correspondence with the investigators. DATA SYNTHESIS Data were combined from 11 studies and effect estimates were pooled using a random-effects model meta-analysis, with heterogeneity assessed with the I(2) statistic. Data were available on 65,229 participants followed for approximately 244,000 person-years, during which 2793 deaths occurred. The use of statins in this high-risk primary prevention setting was not associated with a statistically significant reduction (risk ratio, 0.91; 95% confidence interval, 0.83-1.01) in the risk of all-cause mortality. There was no statistical evidence of heterogeneity among studies (I(2) = 23%; 95% confidence interval, 0%-61% [P = .23]). CONCLUSION This literature-based meta-analysis did not find evidence for the benefit of statin therapy on all-cause mortality in a high-risk primary prevention set-up.

[1]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[2]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[3]  K. Farrar,et al.  Efficacy and safety of cholesterol-lowering treatment , 2006, The Lancet.

[4]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[5]  R. Karas,et al.  Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. , 2007, Journal of the American College of Cardiology.

[6]  J. Gibbs,et al.  JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice , 2005, Heart.

[7]  Edward J. Mills,et al.  Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. , 2008, Journal of the American College of Cardiology.

[8]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[9]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invit , 2007, European heart journal.

[10]  Paul M. Ridker,et al.  Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .

[11]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[12]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[13]  Salim Yusuf,et al.  Lipid lowering for primary prevention , 2009, The Lancet.

[14]  James M. Wright,et al.  Statins for primary prevention of coronary artery disease – Authors' reply , 2007, The Lancet.

[15]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[16]  S. Nissen.  Analyses of cancer data from three ezetimibe trials. , 2009, The New England journal of medicine.

[17]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[18]  J. Salonen,et al.  Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. , 1995, Circulation.

[19]  杏一 水野,et al.  ５．Primary Prevention of Cardiovascular Disease with Pravastatin in Japan（MEGA Study) , 2008 .

[20]  M Alan Brookhart,et al.  Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. , 2006, Archives of internal medicine.

[21]  R. Collins,et al.  The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. , 2008, European heart journal.

[22]  S. Kashiwagi,et al.  Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). , 2002, Journal of the American College of Cardiology.

[23]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[24]  Yasuo Ohashi,et al.  Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial , 2006, The Lancet.

[25]  S. Ward,et al.  A systematic review and economic evaluation of statins for the prevention of coronary events. , 2007, Health technology assessment.

[26]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[27]  J. McEvoy,et al.  Long-term follow-up of the West of Scotland Coronary Prevention Study. , 2008, The New England journal of medicine.

[28]  S. Anderssen,et al.  Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. , 2005, Atherosclerosis.

[29]  Hans L. Hillege,et al.  Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria , 2004, Circulation.

[30]  N. Poulter,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial☆ , 2003 .

[31]  G. Moneta,et al.  Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .

[32]  P. Macfarlane,et al.  Long-term follow-up of the West of Scotland Coronary Prevention Study. , 2007, The New England journal of medicine.

[33]  Barry R. Davis,et al.  Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.

[34]  S. Grundy,et al.  Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus , 2006, Diabetes Care.

[35]  S. Pocock,et al.  Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes , 2006, Diabetes Care.

[36]  Shah Ebrahim,et al.  Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) , 2007 .

[37]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[38]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[39]  H. Mabuchi,et al.  Effect of pravastatin-induced LDL-cholesterol reduction on coronary heart disease and cerebrovascular disease in Japanese: Hokuriku lipid coronary heart disease study-pravastatin atherosclerosis trial (Holicos-PAT). , 2002, Journal of atherosclerosis and thrombosis.

[40]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[41]  Pravastatin use and risk of coronary events and cerebral infarction in japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study. , 2000, Journal of atherosclerosis and thrombosis.

[42]  D. Betteridge,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial☆ , 2004 .

[43]  Diabetes Uk,et al.  JBS 2: Joint British Societies9 guidelines on prevention of cardiovascular disease in clinical practice , 2005 .

[44]  Peter W. Macfarlane,et al.  Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia , 2004 .

[45]  Fernando Costa,et al.  Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus , 2007, Diabetes Care.

[46]  J. Sasaki,et al.  Pravastatin use and risk of coronary events and cerebral infarction in Japanese men with hypercholesterolemia: The Kyushu Lipid Intervention Study (KLIS) , 2000 .

[47]  Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients. , 1993, American Journal of Cardiology.

[48]  R. Arora,et al.  The role of fibrates in the prevention of cardiovascular disease--a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. , 2007, American heart journal.

[49]  J Shepherd,et al.  The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials , 2009, BMJ : British Medical Journal.